Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin, and belongs to calcitonin (CT) superfamily of peptides. Procalcitonin is a 116 amino acid peptide that has an estimated molecular weight of 14.5 kDa. It can be segregated into three parts, namely immature calcitonin, calcitonin carboxyl-terminus peptide-1, and amino terminus of the PCT region. Procalcitonin was first classified by Bernard Roos and Leonard J. Deftos in the early 1970s. Procalcitonin is produced by C cells of the thyroid and by endocrine cells of the lung. In human body, level of unprocessed procalcitonin rises extensively after shock, injury or bacterial infection, which increases the production of procalcitonin in the body.
Click To Continue Reading on Procalcitonin Antibody Market
This might lead to organ dysfunction and call for immediate treatment of the patient. The level of procalcitonin in the body can be diagnosed with wet lab analysis using procalcitonin antibody. On the basis of antibody type, the procalcitonin antibody market is segmented into polyclonal procalcitonin antibody and monoclonal procalcitonin antibody. For instance, according to the World Health Organization (WHO) fact sheet of 2018, cancer was responsible for 8.8 million deaths in 2015 globally. Moreover, according to the World Health Organization report of 2017, around 1.0 million deaths occurred due to HIV related illnesses worldwide. Furthermore, WHO 2017, fact sheet revealed that 71 million people were having chronic hepatitis C infection. Approximately 399,000 people die each year from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma.
These incidences have led to the adoption of new techniques and procedures by research institutes and hospitals for quick diagnosis of the diseases, so that it can be treated within the earliest time frame. Moreover, increasing funding for research and development by commercial market players and government agencies for the development of efficient, safer, and innovative products for the treatment of diseases such as cancer is fueling growth of the procalcitonin antibody market. For instance, in 2018, the U.S government approved US$ 3 billion funds for the National Institutes of Health research and development activities.
Asia Pacific is expected to exhibit significant growth in the procalcitonin antibody market, followed by Europe, owing to increasing healthcare researches and rising geriatric population vulnerable to sepsis disease. According to the Center for Strategic and International Studies, in 2015, 9.5% of the population in China was 65 years or older and as per the United Nations, it is projected to reach to 27.5% by 2050.